Agendia Raises $23M to Build US Sales and Marketing, Support Efforts for MammaPrint

Agendia said the proceeds will serve to "ramp up the US commercial organization, double the sales force, and reinforce marketing, reimbursement, regulatory, and operational support" for its MammaPrint array-based breast cancer recurrence test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.